AI Summary & Key Takeaways
AI InsightIn this study, a case that was followed up in intensive care unit because of COVID-19 disease and had ventricular tachycardia following Tocilizumab treatment was presented.
📌 3 Key Takeaways
Abstract
COVID-19 (Coronavirus Disease-2019) which is dependent on SARS-CoV-2 (Severe Acute Respiratory Syndrome) virus started as a pandemic which affected every sphere of life. The disease progresses more heavily and higher mortality is observed in the COVID-19 patients who had cardiovascular disease before or cardiovascular risk factors (smoking habit, male gender, old age, obesity, diabetes, hyperlipidemia and hypertension). Both COVID-19 disease and the drugs used during treatment lead to cardiac arrhythmia. In this study, a case that was followed up in intensive care unit because of COVID-19 disease and had ventricular tachycardia following Tocilizumab treatment was presented.
Özet
COVID-19 (Coronavirus Disease-2019) SARS-CoV-2 (Severe Acute Respiratory Syndrom) virüsüne bağlı hayatın her alanını etkileyen bir pandemi olarak başladı ve devam etmekte. Daha önce kardiyovasküler hastalığa sahip veya kardiyovasküler risk faktörleri olan (sigara kullanımı, erkek cinsiyet, ileri yaş, obezite, diyabet, hiperlipidemi, hipertansiyon) COVID-19 hastalarında hastalık daha ağır seyretmekte ve daha fazla mortalite izlenmektedir. COVİD-19 hastalığının hem kendisi hem de tedavi esnasında kullanılan ilaçlar kardiyak aritmilere sebep olmaktadır. COVID-19 hastalığı nedeniyle yoğun bakım ünitesinde takip edilen ve tocilizumab tedavisi sonrası ventriküler taşikardi gelişen bir olgu sunulmuştur